Fapon, a pioneering force in the field of life sciences, is set to unveil its extensive range of IVD solutions at the WHX Labs Dubai 2026. Scheduled from February 10 to 13 at the Dubai World Trade Centre, this event serves as an ideal platform for Fapon to showcase its expertise and commitment to advancing healthcare through innovative technology. With over 20 years in the industry, the company is particularly excited to highlight its groundbreaking Alzheimer’s Disease (AD) blood testing solutions, which form a crucial part of its diverse product line. By offering versatile collaboration frameworks, Fapon empowers global partners with comprehensive localization support, enabling the enhancement of local IVD markets.
Local Manufacturing Solutions: A Comprehensive Approach
At WHX Labs Dubai 2026, Fapon will spotlight its Local Manufacturing Solutions, which include platforms for chemiluminescence immunoassay (CLIA), clinical biochemistry, lateral flow assay (LFA), and molecular diagnostics. These solutions feature a full-chain technology transfer process, which covers everything from essential raw materials and reagent solutions to open-system instruments and R&D expertise. By adopting this all-encompassing strategy, Fapon enables its partners to build robust local industrial capabilities, facilitating the journey from research and development to commercialization. This positions them effectively to meet the increasing demands of regional healthcare markets.
Innovative Alzheimer’s Disease Blood Testing
A standout offering is Fapon’s state-of-the-art Alzheimer’s Disease blood testing solution. This product provides a complete array of raw materials and bulk reagents that target crucial biomarkers such as p-tau 217, p-tau 181, Aβ40, Aβ42, GFAP, and NfL. These biomarkers are characterized by their high sensitivity and specificity, establishing a strong correlation with existing clinical diagnostic tests. This innovation allows IVD manufacturers worldwide to develop more reliable and accurate assays for Alzheimer’s Disease, thus enhancing early detection and management options for patients.
Advanced Chemiluminescence Solutions
Fapon will also present its comprehensive chemiluminescence solutions, which include the Shine series of CLIA analyzers. These analyzers, offering throughput capabilities ranging from 120 T/h to 900 T/h, are supported by over 70 proprietary reagent solutions and essential raw materials. Additionally, Fapon will showcase its premium raw material portfolio, which includes recombinant quality controls and calibrators for conditions such as RF, HbA1c, and HIV. Furthermore, the introduction of LAMP solutions for rapid molecular diagnostics highlights Fapon’s commitment to strong foundational support in diagnostic development.
Commitment to Global Healthcare Advancement
Fapon’s dedication to innovation is further underscored by its state-of-the-art facilities, which span over 100,000 square meters, along with a robust global R&D and manufacturing network. The company proudly serves more than 70 countries and partners with over 2,500 organizations worldwide. Fapon is committed to fostering collaborative efforts that aim to enhance regional healthcare systems and drive industry progress.
In conclusion, Fapon continues to redefine the landscape of diagnostics and therapeutics through its innovative, AI-driven models. By integrating cutting-edge technology with practical application, the company accelerates the discovery of novel biomarkers and the development of precise medical solutions. To learn more about Fapon’s initiatives and offerings, connect with us on LinkedIn or visit our website.